Consistently, ectopic TRIM71 suppressed ovarian cancer cell proliferation in vitro and ovarian tumor growth in vivo, whereas RNAi- or CRISPR-Cas9-mediated ablation of endogenous TRIM71 promoted ovarian cancer cell growth and migration in vitro and/or in vivo. This evidence concerns the gene TRIM71 and ovarian cancer.